Who are Loceryl NL 12 weeks's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Naftin, NAFT500 (pediatric), Lotrimin Ultra®, Terbinafine Tablets, Naftifine Hydrochloride Cream 2%, terbinafine hydrogen chloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/loceryl-nl-12-weeks.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Loceryl NL 12 weeks — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Loceryl NL 12 weeks (Loceryl NL 12 weeks) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allylamine antifungal. Area: Dermatology / Infectious Disease.

marketed Allylamine antifungal Lanosterol 14α-demethylase (CYP51) Dermatology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Loceryl NL 12 weeks (Loceryl NL 12 weeks) — Galderma R&D. Loceryl is a topical antifungal that inhibits fungal sterol synthesis by blocking lanosterol 14α-demethylase, disrupting the fungal cell membrane.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Loceryl NL 12 weeks TARGET	Loceryl NL 12 weeks	Galderma R&D	marketed	Allylamine antifungal	Lanosterol 14α-demethylase (CYP51)
Naftin	NAFTIFINE	Legacy Pharma	marketed	Allylamine Antifungal	Sigma non-opioid intracellular receptor 1	1988-01-01
NAFT500 (pediatric)	NAFT500 (pediatric)	Merz North America, Inc.	marketed	Allylamine antifungal	Squalene epoxidase
Lotrimin Ultra®	Lotrimin Ultra®	Sun Pharmaceutical Industries, Inc.	marketed	Allylamine antifungal	Squalene epoxidase
Terbinafine Tablets	Terbinafine Tablets	Oregon Health and Science University	marketed	Allylamine antifungal	Squalene epoxidase
Naftifine Hydrochloride Cream 2%	Naftifine Hydrochloride Cream 2%	Sun Pharmaceutical Industries, Inc.	phase 3	Allylamine antifungal	Squalene epoxidase
terbinafine hydrogen chloride	terbinafine hydrogen chloride	Novartis	phase 3	Allylamine antifungal	Squalene epoxidase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allylamine antifungal class)

Merz North America, Inc. · 3 drugs in this class
Sun Pharmaceutical Industries, Inc. · 2 drugs in this class
Bayer · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Pak Emirates Military Hospital · 1 drug in this class
Novartis · 1 drug in this class
Galderma R&D · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Loceryl NL 12 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/loceryl-nl-12-weeks. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing